benzydamine
Small moleculeexperimental
Benzydamine, available as the hydrochloride salt, is a locally acting nonsteroidal anti-inflammatory drug (NSAID) with local anaesthetic and analgesic properties for pain relief and anti-inflammatory treatment of inflammatory conditions of the mouth and throat. It falls under class of chemicals known as indazole. — Wikipedia
Clinical trial activity
32 trials · 30 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
12
Phase 3
5
Phase 4
10
Earliest trial started Sep 1, 1998 (NCT02178293)
Timeline
Indications
Approved for
Studied for
- Cough · Early Phase 1
- Drug-Related Side Effects and Adverse Reactions · Phase 2
- Head and Neck Neoplasms · Phase 4
- Healthy Volunteers · Phase 1
- Intubation · Phase 4
- Mucositis · Phase 4
- Nasopharyngitis · Phase 2
- Pain · Phase 4
- Pharyngitis · Phase 4
- Postoperative Care · Early Phase 1
- Postoperative Nausea and Vomiting · Phase 4
- Quality of Life · Phase 4
- Radiation Effects · Phase 3
- Respiratory Tract Infections · Early Phase 1
- Stomatitis · Phase 3
- Streptococcal Infections · Phase 4
- Tooth Abnormalities · Phase 4
Mechanism of action
Serotonin 2 receptors; 5-HT2a & 5-HT2c activator
- CyclooxygenaseINHIBITOR
Cyclooxygenase inhibitor
Benzydamine is a nonsteroidal anti-inflammatory drug that acts partly through an inhibitory effect on the phospholipase A2 by diminishing the liberation of arachidonic acid from phospholipids, and partly as a weak inhibitor of prostaglandin G/H synthase 1 and 2 by reducing the production of prostaglandins.
Weak inhibitotor of COX-1 and COX-2.
Chemistry & pharmacology
Loading structure…
SMILES
CN(C)CCCOc1nn(Cc2ccccc2)c2ccccc12- Mol. weight
- 309.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL12610 ↗
- WikipediaBenzydamine ↗
- ChEMBLCHEMBL1528134 ↗
Also known as
- af-864
- af-864
- benzidamine
- benzidamine hydrochloride
- benzidamine hydrochloride
- benzindamine
- benzydamide
- benzydamine
- benzydamine
- benzydamine
- benzydamine
- benzydamine
- benzydamine
- benzydamine
- benzydamine hcl
- benzydamine hcl
- benzydamine hcl
- benzydamine hcl
- benzydamine hcl
- benzydamine hcl
- benzydamine hydrochloride
- benzydamine hydrochloride
- benzydamine hydrochloride
- benzydamine hydrochloride
- benzydamine hydrochloride
- difflam
- difflam
- difflam-p
- lozamine
- tantum
- tantum
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07199543 | Phase 1 | Apr 13, 2025 | Angelini, Cross Research S.A. |
| NCT06676748 | Early Phase 1 (Phase 1) | Nov 30, 2024 | KK Women's and Children's Hospital |
| NCT06843018 | Phase 2 | Nov 14, 2024 | Valenta Pharm JSC |
| NCT06862817 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2023 | Minia University |
| NCT05955885 | Early Phase 1 (Phase 1) | Jul 1, 2023 | Reckitt Benckiser Pharmaceutical, University of Melbourne |
| NCT06879366 | Phase 4 | Jun 1, 2023 | October 6 University |
| NCT05323058 | Phase 2 | Jul 31, 2022 | Cairo University |
| NCT05338398 | Phase 1/Phase 2 (Phase 2) | Apr 15, 2022 | E2Bio Life Sciences, LLC |
| NCT05343429 | Phase 4 | Apr 1, 2022 | Rehman Medical Institute - RMI, University of Karachi |
| NCT05055726 | Phase 4 | Oct 31, 2021 | Angelini, PPD |
| NCT05034068 | Early Phase 1 (Phase 1) | Oct 31, 2021 | Al Azhar University, Assiut University |
| NCT04941976 | Phase 4 | Aug 13, 2020 | Angelini, Zak-Pharma Dienstleistung Ges.m.b.H. |
| NCT04303312 | Phase 3 | Apr 30, 2020 | Cairo University |
| NCT04685395 | Phase 3 | Dec 26, 2019 | Cairo University |
| NCT04308161 | Phase 2 | Nov 2, 2019 | Alexandria University |
| NCT04317183 | Phase 2 | May 15, 2019 | Alexandria University |
| NCT04537819 | N/A | Mar 20, 2019 | Bionorica, Ivano-Frankivsk National Medical University |
| NCT04373421 | Phase 4 | Jan 15, 2019 | Yuzuncu Yıl University |
| NCT04167592 | N/A | Aug 1, 2018 | University of Indonesia |
| NCT03833570 | Phase 2 | Jan 12, 2018 | Alexandria University |
Showing 20 of 32 trials
Page 1 / 2
Organizations
Research & Development (30)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Angelini | For profit | 7 | 6 | 3 | 2003 |
| Cross Research S.A. | For profit | 4 | 0 | 1 | 2015 |
| Alexandria University | Academic/Hospital | 3 | 3 | 1 | 2018 |
| Cairo University | Academic/Hospital | 3 | 3 | 2 | 2019 |
| Al Azhar University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Assiut University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Bionorica | For profit | 1 | 0 | 1 | 2019 |
| Boehringer Ingelheim | For profit | 1 | 1 | 1 | 1998 |
| Chang Gung University | Academic/Hospital | 1 | 1 | 1 | 2014 |
| E2Bio Life Sciences, LLC | For profit | 1 | 1 | 1 | 2022 |
| Ivano-Frankivsk National Medical University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| KK Women's and Children's Hospital | Academic/Hospital | 1 | 1 | 1 | 2024 |
| McMaster University | Academic/Hospital | 1 | 1 | 1 | 2009 |
| McNeil | For profit | 1 | 1 | 1 | 2003 |
| Minia University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| National University of Malaysia | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Near East University, Turkey | Academic/Hospital | 1 | 1 | 1 | 2017 |
| October 6 University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| PPD | For profit | 1 | 0 | 1 | 2021 |
| Prince of Songkla University | Academic/Hospital | 1 | 1 | 1 | 2011 |
30 organizations
Page 1 / 2